ANI Pharmaceuticals, Inc. (ANIP) financial statements and ratios from SEC XBRL: revenue $1.0B (TTM), net margin 8.9%, revenue growth 25.9% YoY, P/E 15.3. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $883.37M |
| Revenue (TTM) | $1.0B |
| Net Margin | 8.9% |
| Operating Margin (TTM) | 15.4% |
| Net Debt / EBITDA | -0.2 |
| Revenue Growth (YoY) | 25.9% |
| EPS Growth (YoY) | 194.6% |
| FCF Growth (YoY) | -25.3% |
| P/E Ratio | 15.3 |
| EV / EBITDA | 6.7 |
| Price / Book | 2.77 |
| Price / Sales | 1.69 |
| FCF Yield | 10.5% |
| Altman Z-Score | 2.37 (grey) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
ANIP overview · ANIP earnings · ANIP KPIs · ANIP documents · ANIP ownership · ANIP peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.